CYCN

Cyclerion Therapeutics, Inc.

2.74 USD
+0.49 (+21.78%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cyclerion Therapeutics, Inc. stock is down -2.14% since 30 days ago. The next earnings date is Jul 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 June’s closed higher than May.

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.